GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Cyclically Adjusted Price-to-FCF

Alkermes (Alkermes) Cyclically Adjusted Price-to-FCF : 308.50 (As of Apr. 27, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Alkermes Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), Alkermes's current share price is $24.68. Alkermes's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.08. Alkermes's Cyclically Adjusted Price-to-FCF for today is 308.50.

The historical rank and industry rank for Alkermes's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

ALKS' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 298.13   Med: 551.02   Max: 989.1
Current: 310.02

During the past years, Alkermes's highest Cyclically Adjusted Price-to-FCF was 989.10. The lowest was 298.13. And the median was 551.02.

ALKS's Cyclically Adjusted Price-to-FCF is ranked worse than
95.38% of 325 companies
in the Drug Manufacturers industry
Industry Median: 32.81 vs ALKS: 310.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Alkermes's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $0.540. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.08 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alkermes Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Alkermes's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Cyclically Adjusted Price-to-FCF Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 539.22 - 348.46

Alkermes Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 936.27 528.13 348.46

Competitive Comparison of Alkermes's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Alkermes's Cyclically Adjusted Price-to-FCF falls into.



Alkermes Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Alkermes's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=24.68/0.08
=308.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Alkermes's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.54/120.1096*120.1096
=0.540

Current CPI (Dec. 2023) = 120.1096.

Alkermes Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.064 100.573 -0.076
201406 0.020 100.773 0.024
201409 -0.114 100.474 -0.136
201412 0.002 99.576 0.002
201503 -0.058 99.975 -0.070
201506 -0.198 100.573 -0.236
201509 -0.277 100.274 -0.332
201512 -0.091 99.676 -0.110
201603 -0.459 99.676 -0.553
201606 -0.259 101.072 -0.308
201609 0.021 100.274 0.025
201612 -0.015 99.676 -0.018
201703 -0.151 100.374 -0.181
201706 -0.220 100.673 -0.262
201709 0.043 100.474 0.051
201712 0.118 100.075 0.142
201803 -0.293 100.573 -0.350
201806 0.098 101.072 0.116
201809 0.110 101.371 0.130
201812 0.276 100.773 0.329
201903 -0.009 101.670 -0.011
201906 -0.249 102.168 -0.293
201909 0.073 102.268 0.086
201912 0.064 102.068 0.075
202003 -0.380 102.367 -0.446
202006 -0.094 101.769 -0.111
202009 0.338 101.072 0.402
202012 0.389 101.072 0.462
202103 -0.333 102.367 -0.391
202106 0.156 103.364 0.181
202109 0.483 104.859 0.553
202112 0.126 106.653 0.142
202203 0.085 109.245 0.093
202206 -0.075 112.734 -0.080
202209 -0.060 113.431 -0.064
202212 -0.055 115.425 -0.057
202303 -0.171 117.618 -0.175
202306 1.201 119.611 1.206
202309 0.496 120.708 0.494
202312 0.540 120.110 0.540

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alkermes  (NAS:ALKS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Alkermes Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Alkermes's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (Alkermes) Business Description

Industry
Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451